DNA methylation in breast cancer.

  title={DNA methylation in breast cancer.},
  author={X Yang and L. Yan and Nancy E. Davidson},
  journal={Endocrine-related cancer},
  volume={8 2},
Like all cancers, breast cancer is considered to result in part from the accumulation of multiple genetic alterations leading to oncogene overexpression and tumor suppressor loss. More recently, the role of epigenetic change as a distinct and crucial mechanism to silence a variety of methylated tissue-specific and imprinted genes has emerged in many cancer types. This review will briefly discuss basic aspects of DNA methylation, recent advances in DNA methyltransferases, the role of altered… 

Tables from this paper

DNA methylation in breast and colorectal cancers
A brief overview of the mechanism of DNA methylation, its relationship to extrinsic stimulation including dietary intake and aging, and of abnormally methylated DNA in breast and colorectal cancers are provided, which could be used as prognostic and diagnostic markers.
Epigenetic Signatures of Breast Cancer Genes
Different modes of epigenetic regulation including DNA methylation, histone modification, polycomb group of proteins, and non-coding RNAs are provided and the epigenetic regulatory mechanisms of various breast cancer related genes are discussed in detail.
Targeting DNA methylation for treating triple-negative breast cancer
DNA methyltransferase inhibitors reactivate silenced tumor suppressor genes and result in tumor growth arrest, with therapeutic effects observed in patients with hematologic malignancies.
Diagnostic utility of epigenetics in breast cancer - A review.
Breast Cancer Epigenetics: Biomarkers and Therapeutic Potential
In this chapter, we review the central roles that epigenetic mechanisms, including DNA methylation, histone posttranslational modifications, and nucleosome positioning, play in governing gene
DNA methylation and cancer.
  • P. M. Das, R. Singal
  • Biology, Chemistry
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
The contribution of dietary folate and methylene terahydrofolate reductase polymorphisms to methylation patterns in normal and cancer tissues is under intense investigation and may be of potential use in early detection of tumors and for determining the prognosis.
Epigenetics and Three Main Clinical Aspects of Breast Cancer Management
Epigenetic signatures in tumor tissues can classify tumors precisely and may provide new classification beyond conventional histopathological classifications, they are appropriate targets for epidrugs (DNMT inhibitors and HDACis) in breast cancer treatment.


Promoter-region hypermethylation and gene silencing in human cancer.
It is apparent that alterations in DNA methylation are a fundamental molecular change associated with the neoplastic process and have important biologic implications for tumor initiation and progression and an epigenetic process which, in conjunction with genetic alterations, appears to drive the process of neoplasia.
Methylation of the BRCA1 gene in sporadic breast cancer.
Hypermethylation was observed in two of seven sporadic breast carcinomas but not in any normal tissues, consistent with an important role for epigenetic mechanisms in human cancer.
Genomic instability: first step to carcinogenesis.
Genomic instability including genetic and/or epigenetic alterations may be the first step in carcinogenesis and knowledge of these biochemical mechanisms are likely to lead to more effective cancer diagnosis and therapy.
Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer.
In the translational arena, the promoter hypermethylation changes hold great promise as DNA tumor markers and their potentially reversible state creates a target for cancer therapeutic strategies involving gene reactivation.
Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers.
In tumors, de novo methylation of the 5' CpG island is a frequent mode of inactivation of CDKN2/p16 and this alteration of p16 in colon cancer was particularly striking, since inactivation does not occur through homozygous deletion in this tumor type.
CpG methylation is maintained in human cancer cells lacking DNMT1
It is shown that cells lacking DNMT1 exhibited markedly decreased cellular DNA methyltransferase activity, but there was only a 20% decrease in overall genomic methylation, indicating thatDNMT1 has an unsuspected degree of regional specificity in human cells and that methylating activities other than DN MT1 can maintain the methylation of most of the genome.
High expression of the DNA methyltransferase gene characterizes human neoplastic cells and progression stages of colon cancer.
Increases in DNA methyltransferase gene expression precede development of colonic neoplasia and continue during progression of colonIC neoplasms, which may play a role in the genetic instability of cancer and mark early events in cell transformation.
Involvement of DNA methylation in human carcinogenesis.
Recent findings and hypotheses about the function of 5mC in DNA are described with the focus on its involvement in human carcinogenesis.
Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells.
It is suggested that abnormal methylation could account for transcriptional inactivation of the estrogen receptor gene and subsequent hormone resistance in some human breast cancers.